News EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023 Staff September 11, 2023 Continue Reading Previous Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive OfficerNext Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer More Stories Brain Clinical Trial News Pharmaceutical Alzheon Raises $100 Million Series E Financing Round to Advance Development and Commercialization of Oral Tablet ALZ-801/Valiltramiprosate for Treatment of Alzheimer’s Disease Staff June 12, 2024 Healthcare Mental Health News Pharmaceutical Canary Speech Secures $13 Million in Series A Funding to Change How the World’s Top Healthcare Organizations Screen for Mental Wellness and Cognitive Health Staff June 12, 2024 Mental Health News Twenty Percent Of The World’s Employees Experience Loneliness While Global Employee Engagement Stagnated And Employee Wellbeing Declined Staff June 12, 2024
